שולי רווח נקי Renalytix, plc (RNLX)

סמלים רשמיים של חברת Renalytix, plc (RNLX)

Renalytix Plc (RNLX) develops AI tools for the early detection of renal pathologies in diabetic patients. The company's strategy is based on predictive analytics that prevent the need for dialysis. The integral net margin indicator demonstrates the current efficiency of this model, where 0.00 serves as the base parameter value. Further momentum relies on government subsidies and insurance contracts to mitigate capital deficits.

Renalytix Plc (RNLX) - שולי רווח נקי ממכירות מ-04.07.2022 עד 19.10.2024

פילוחים אנליטיים של חברת Renalytix Plc

- שער מניה ותחזית מחירי מומחים:
הערכת שווי פונדמנטלית של החברה:renalytix.com - RNLX
מוצרים מוגמרים של Renalytix AI

To select high-quality assets, an investor must evaluate the efficiency of converting revenue into net income. This metric measures the profit share of every dollar of sales, reflecting the fundamental resilience of the business model. For Renalytix Plc (RNLX), stable access to developed markets minimizes operating expenses. Analyzing the net margin allows for a comparison of current profitability against market expectations. The net margin trend helps determine the optimal entry point for the asset.